CROP reports 78% five-year survival with SBRT and intermittent ADT in prostate cancer
In oligometastatic hormone-sensitive prostate cancer, comprehensive SBRT plus intermittent ADT produced 78.2% five-year survival and 15.2% failure-free survival.
In oligometastatic hormone-sensitive prostate cancer, comprehensive SBRT plus intermittent ADT produced 78.2% five-year survival and 15.2% failure-free survival.
In 473 pancreatic cancer patients, SBRT achieved 82% one-year local control, with higher biologically effective dose associated with better response.
In SRAM, weekly pelvic SBRT produced similar grade ≥2 toxicity but worse bowel quality-of-life scores at 9 and 12 months versus IMRT.
In 70 patients, a 7.5-Gy stereotactic tumor-bed boost before whole-breast RT produced 7% grade 2 fibrosis and no grade ≥3 late toxicity.
In a 23-patient phase I study, five-fraction partial-breast SBRT produced no in-breast recurrences, while favorable cosmesis declined to 73.7% at three years.
In 51 patients with unresectable stage III NSCLC, an adaptive SBRT boost achieved 62.8% two-year locoregional control, with hemoptysis raising safety concerns.
In 115 peripheral lung SBRT patients, five-year survival was 36% for left-sided lesions versus 70% for right-sided lesions, an exploratory association.
In 34 patients, two-year local failure after bone SBRT was 14.1%, while progression-free survival was only 8.8%.
In 448 patients with unresected early-stage NSCLC, pembrolizumab added to SBRT did not improve event-free survival but substantially increased severe toxicity.
A comprehensive review integrates randomized HCC radiotherapy evidence with practical recommendations for liver-function assessment, dose constraints, motion management and high-risk treatment.
Among 202 irradiated prostate cancer metastases, 54% developed local failure, while severe late radiation-attributed toxicity occurred after 2% of lesions.
In 18 evaluable patients, papaverine combined with lung SBRT achieved 100% estimated two-year local control, with two dose-limiting toxicities.
In 25 peripheral lung SBRT plans, PlanIQ classified 68% of achieved V20 values as theoretically impossible under standard reference-dose settings.
Acute grade ≥2 urinary toxicity occurred in 64.7% of patients with periurethral calcifications versus 23.3% without them.
Periorbital SBRT achieved 88% one-year local control with reported vision preservation in all 26 patients, although severe dermatitis and ocular complications occurred.